261 related articles for article (PubMed ID: 25049247)
1. Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.
Duarte RF; López-Jiménez J; Cornely OA; Laverdiere M; Helfgott D; Haider S; Chandrasekar P; Langston A; Perfect J; Ma L; van Iersel ML; Connelly N; Kartsonis N; Waskin H
Antimicrob Agents Chemother; 2014 Oct; 58(10):5758-65. PubMed ID: 25049247
[TBL] [Abstract][Full Text] [Related]
2. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.
Cornely OA; Duarte RF; Haider S; Chandrasekar P; Helfgott D; Jiménez JL; Candoni A; Raad I; Laverdiere M; Langston A; Kartsonis N; Van Iersel M; Connelly N; Waskin H
J Antimicrob Chemother; 2016 Mar; 71(3):718-26. PubMed ID: 26612870
[TBL] [Abstract][Full Text] [Related]
3. A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers.
Krishna G; Ma L; Martinho M; Preston RA; O'Mara E
J Antimicrob Chemother; 2012 Nov; 67(11):2725-30. PubMed ID: 22833639
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Safety of Posaconazole Tablet Formulation in Chinese Participants at High Risk for Invasive Fungal Infection.
Liu K; Wu D; Li J; Chen H; Ning H; Zhao T; Dai H; Chen L; Mangin E; Winchell GA; Waskin H; Jiang J; Qiu Y; Zhao XM
Adv Ther; 2020 May; 37(5):2493-2506. PubMed ID: 32319040
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.
Cornely OA; Robertson MN; Haider S; Grigg A; Geddes M; Aoun M; Heinz WJ; Raad I; Schanz U; Meyer RG; Hammond SP; Mullane KM; Ostermann H; Ullmann AJ; Zimmerli S; Van Iersel MLPS; Hepler DA; Waskin H; Kartsonis NA; Maertens J
J Antimicrob Chemother; 2017 Dec; 72(12):3406-3413. PubMed ID: 28961714
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
Krishna G; AbuTarif M; Xuan F; Martinho M; Angulo D; Cornely OA
Pharmacotherapy; 2008 Oct; 28(10):1223-32. PubMed ID: 18823218
[TBL] [Abstract][Full Text] [Related]
7. Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.
Maertens J; Cornely OA; Ullmann AJ; Heinz WJ; Krishna G; Patino H; Caceres M; Kartsonis N; Waskin H; Robertson MN
Antimicrob Agents Chemother; 2014 Jul; 58(7):3610-7. PubMed ID: 24733463
[TBL] [Abstract][Full Text] [Related]
8. A Population Pharmacokinetic Model for a Solid Oral Tablet Formulation of Posaconazole.
van Iersel MLPS; Rossenu S; de Greef R; Waskin H
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29712663
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation.
Döring M; Cabanillas Stanchi KM; Queudeville M; Feucht J; Blaeschke F; Schlegel P; Feuchtinger T; Lang P; Müller I; Handgretinger R; Heinz WJ
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1281-1292. PubMed ID: 28258343
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain.
Cámara R; Gozalbo I; Jurado M; Sanz J; Aragón B; Grau S
Adv Ther; 2017 Sep; 34(9):2104-2119. PubMed ID: 28808915
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
AbuTarif MA; Krishna G; Statkevich P
Curr Med Res Opin; 2010 Feb; 26(2):397-405. PubMed ID: 20001450
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial.
Groll AH; Abdel-Azim H; Lehrnbecher T; Steinbach WJ; Paschke A; Mangin E; Winchell GA; Waskin H; Bruno CJ
Int J Antimicrob Agents; 2020 Sep; 56(3):106084. PubMed ID: 32682946
[TBL] [Abstract][Full Text] [Related]
13. Posaconazole versus voriconazole as antifungal prophylaxis during induction therapy for acute myelogenous leukemia or myelodysplastic syndrome.
Phillips K; Cirrone F; Ahuja T; Siegfried J; Papadopoulos J
J Oncol Pharm Pract; 2019 Mar; 25(2):398-403. PubMed ID: 30319061
[TBL] [Abstract][Full Text] [Related]
14. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D
N Engl J Med; 2007 Jan; 356(4):348-59. PubMed ID: 17251531
[TBL] [Abstract][Full Text] [Related]
15. A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia.
Arrieta AC; Sung L; Bradley JS; Zwaan CM; Gates D; Waskin H; Carmelitano P; Groll AH; Lehrnbecher T; Mangin E; Joshi A; Kartsonis NA; Walsh TJ; Paschke A
PLoS One; 2019; 14(3):e0212837. PubMed ID: 30913226
[TBL] [Abstract][Full Text] [Related]
16. Posaconazole plasma concentrations in pediatric patients receiving antifungal prophylaxis during neutropenia.
Döring M; Cabanillas Stanchi KM; Klinker H; Eikemeier M; Feucht J; Blaeschke F; Schwarze CP; Ebinger M; Feuchtinger T; Handgretinger R; Heinz WJ
Med Mycol; 2017 Jun; 55(4):375-384. PubMed ID: 27703016
[TBL] [Abstract][Full Text] [Related]
17. Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation.
Liebenstein TK; Widmer KM; Fallon MJ
J Oncol Pharm Pract; 2018 Dec; 24(8):599-603. PubMed ID: 28768441
[TBL] [Abstract][Full Text] [Related]
18. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension.
Krishna G; Ma L; Martinho M; O'Mara E
Antimicrob Agents Chemother; 2012 Aug; 56(8):4196-201. PubMed ID: 22615291
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in Sweden.
Lundberg J; Höglund M; Björkholm M; Åkerborg Ö
Clin Drug Investig; 2014 Jul; 34(7):483-9. PubMed ID: 24820968
[TBL] [Abstract][Full Text] [Related]
20. Posaconazole delayed-release tablets in paediatric haematology-oncology patients.
Mauro M; Colombini A; Perruccio K; Zama D; D'Amico MR; Calore E; Carraro F; Muggeo P; Tridello G; Baretta V; Cesaro S
Mycoses; 2020 Jun; 63(6):604-609. PubMed ID: 32246512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
